STAR and neoplasm: Considering the transient in vivo tumor control and un-sustained T-cell proliferation obtained with TCR-1 or STAR-3 T cells, we sought to identify additional co-stimulatory components that might augment and prolong T-cell activity against cancer cells expressing low densities of surface antigen.